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Sodium glucose co-transporter 2 (SGLT2) inhibitors have been associated with increased
serum ketone body levels in patients with type 2 diabetes mellitus (T2DM). In the present
analysis we evaluated serum ketone body levels and variability in 1278 Japanese patients
with T2DM treated with canagliflozin 100 or 200 mg. Similar mean increases in ketone
body concentrations of ~2-fold were seen with both canagliflozin doses. The median (inter-
quartile range) percent change from baseline was 62% (0;180) for acetoacetate and 78%
(2;236) for β-hydroxybutyrate. Approximately two-thirds of the variability in each ketone
measure was attributed to intra-subject variability. Intra-subject variability was higher for
serum ketones than other metabolites. Patients in the lowest response tertile exhibited no
increase in ketones. Those in the highest response tertile tended to be male and have
higher fasting plasma glucose levels, lower insulin levels, and longer T2DM duration at
baseline. Moreover, changes in serum ketones were not fully explained by changes in
plasma fatty acids, suggesting downstream effects of SGLT2 inhibition on hepatic metabo-
lism that favour ketogenesis. In summary, increases in serum ketone bodies with canagliflo-
zin were greater and more variable than changes in other metabolic measures in Japanese
patients with T2DM.
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1 | INTRODUCTION
The ketone bodies β-hydroxybutyrate (BHB) and acetoacetate (AcAc)
are produced primarily in the liver and are utilized by the heart, mus-
cles, kidneys and brain for energy metabolism when carbohydrate
supply is limited (eg, fasting, after exercise).1 Overnight-fasted serum
ketone body concentrations are typically ~50 to 200 μM, but dra-
matic increases can be seen during prolonged fasting (~1 mM) or dia-
betic ketoacidosis (DKA; up to ~20 mM).1
Ketogenesis is often viewed as a proxy for hepatic fat oxidation
and as a spillover metabolic pathway in the liver.2 Under conditions
of reduced insulin concentrations, adipose lipolysis and delivery of
fatty acyl chains to hepatocytes is increased. After transport of fatty
acyl chains across the mitochondrial membranes and β-oxidation, the
mitochondrial isoform of 3-hydroxymethylglutaryl-CoA synthase 2
(HMGCS2) catalyses the fate-committing condensation reaction in
ketogenesis. HMGCS2 enzyme activity is regulated through multiple
allosteric and covalent post-translational modifications, and an active
area of research investigation is whether these inputs might be
responsible for intra-subject and/or inter-subject variation in keto-
genesis, beyond that which can be explained by free fatty acid (FFA)
availability to the liver.2 In conditions of DKA, the glucagon/insulin
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ratio is often dramatically increased and leads to increased ketone
production; in addition, the abundance and function of succinyl-CoA
oxoacid transferase, the key enzyme required for extrahepatic ketone
body oxidation, become diminished, limiting ketone body disposal.1
Ketone bodies are a preferred energy substrate for the heart and
their use is increased in failing hearts. It has been hypothesized that,
in the setting of heart failure, the energy-starved myocardium adapts
its fuel metabolism from primarily fatty acid oxidation to ketone bod-
ies to maintain adequate fuel supplies.3
Sodium glucose co-transporter 2 (SGLT2) inhibitors lower the renal
threshold for glucose, thereby increasing urinary glucose excretion
(UGE) and lowering blood glucose levels in patients with type 2 diabetes
mellitus (T2DM); increased UGE also results in mild osmotic diuresis and
a net caloric loss, leading to reductions in blood pressure (BP) and body
weight (BW).4 Increased serum concentrations of ketone bodies have
also been observed after SGLT2 inhibitor treatment, with high between-
subject variability.5–7 SGLT2 inhibitors have been associated with rare
cases of DKA,8 with potential risk factors including inappropriate reduc-
tions in insulin doses and low carbohydrate intake6; however, in light of
the positive effects of the SGLT2 inhibitors on cardiovascular
outcomes,9,10 it has been hypothesized that SGLT2 inhibition shifts car-
diac energy utilization away from glucose and towards fatty acids and
ketone bodies, which may improve overall cardiac energetics, thereby
leading to reductions in adverse cardiovascular and renal outcomes in
patients with T2DM.11
In relatively small and short-term studies, the increases in serum
ketone bodies observed in response to SGLT2 inhibitor treatment
were found to be highly variable.12,13 The extent to which this vari-
ability is attributable to inter-subject vs intra-subject variability was
not assessed in these studies. The aim of the present analysis was to
characterize the inter- and intra-subject variability in serum ketone
body responses in patients with T2DM treated with canagliflozin.
2 | METHODS
2.1 | Study design and patient population
The present analysis was based on results from post hoc analyses
that were performed using data from a 52-week, multicentre, open-
label study of canagliflozin in 1299 Japanese patients with T2DM
(ClinicalTrials.gov identifier: NCT01387737).5 Patients on diet/exer-
cise or diet/exercise plus an oral antihyperglycaemic drug were ran-
domized to receive canagliflozin 100 or 200 mg while continuing
prior therapy; the treatment period was 52 weeks and there was a
follow-up period of 2 weeks after the treatment period. The study
was conducted in accordance with Good Clinical Practice guidelines
and the Pharmaceutical Affairs Law in Japan and complied with the
ethical principles of the Declaration of Helsinki. The present analyses
included only patients with available ketone body data.
2.2 | Endpoints and statistical analyses
Serum ketone bodies (BHB, AcAc and total ketone bodies [TKB]) and
other metabolic variables were measured every 4 weeks for
52 weeks. All laboratory measurements were performed at a central
laboratory (SRL Inc, Tokyo, Japan) according to standard operating
procedures. Data from all patients (including those who discontinued
at some point during the study) were included, and no imputation of
missing values was performed.
Changes in ketone bodies and the other metabolic variables were
modelled using a random effects model of the form:
ΔKBij = μ+ βj + εij,
where ΔKBij is the change from baseline at the i
th time in subject j, μ
is the mean change for all subjects/visits, βj is a subject-specific ran-
dom effect (the difference between the mean change in subject j and
the mean change in the population), and εij is a visit-specific deviation







was used to characterize intra- and inter-subject variability for the
different measures. As σ2β provides a measure of inter-subject vari-
ability and σ2ϵ provides a measure of intra-subject variability, high
values of ICC (close to 1) occur when most of the variability in the
response can be accounted for by between-subject variability with
relatively little variation over time within each subject, whereas lower
values of ICC occur when there is more within-subject variability in
the response over time. The random effects models were used to
divide subjects into tertiles of ketone response based on the βj
parameters.
To assess the extent to which changes in serum ketone bodies
could be directly related to changes in other measurements, stepwise
regression was performed between the change from baseline in
ΔTKB and the changes in other measurements (ΔFFA, fasting plasma
glucose [ΔFPG], triglycerides [ΔTG], LDL cholesterol [ΔLDL-C], HDL
cholesterol [ΔHDL-C], ΔBW, systolic BP [ΔSBP], and Δinsulin) using
all post-baseline measurements; gender was also included in the
model. All calculations were performed in MATLAB version 9.0
(MathWorks®, Natick, Massachusetts).
3 | RESULTS
3.1 | Patient population
Of 1299 patients who participated in the study, 1278 had ketone
body data; baseline characteristics were balanced between the cana-
gliflozin 100 and 200 mg groups (Table S1). The median (interquartile
range [IQR]) BHB and AcAc concentrations at baseline were
55 (34;97) μM and 28 (19;44) μM, respectively, for patients included
in this analysis.
3.2 | Ketone body changes
Similar median increases in BHB and AcAc concentrations were seen
with both canagliflozin doses over 52 weeks; median concentrations
were approximately doubled with canagliflozin treatment (Figure 1A).
Canagliflozin 100 and 200 mg were associated with an initial increase
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in both BHB and AcAc from baseline to week 4; the increase was
sustained over 52 weeks, with modestly greater mean increases seen
at the earlier visits.
The median percent change from baseline in ketone body con-
centrations with canagliflozin (pooled 100 and 200 mg) was much
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FIGURE 1 A, Serum ketone body concentrations (top) and change from baseline values (bottom) and B, change from baseline for ketone bodies,
divided into tertiles of response. Values shown are median (interquartile range). AcAc, acetoacetate; BHB, β-hydroxybutyrate
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increases were 78%, 62% and 73% with BHB, AcAc and TKB, respec-
tively. Only one-third of the variability in BHB, AcAc and TKB was
attributed to inter-subject variability; the remaining two-thirds of the
variability was attributed to intra-subject variability. In contrast, vari-
ability in FPG, glycated haemoglobin (HbA1c) and insulin were mainly
attributed to inter-subject variability, while variability in FFA was
nearly evenly split between inter- and intra-subject variability.
To further assess variability in ketone body concentrations and
explore which baseline factors were associated with the largest
changes in ketone bodies, patients were stratified into tertiles based
on average ketone body response. In the lowest tertile of ketone
response, no notable changes in mean ketone concentrations were
observed at any time point (Figure 1B). Patients in the intermediate
tertile of ketone response had changes in ketone body concentra-
tions that were generally steady over time. Among patients in the
highest tertile of ketone response, changes in ketone body concen-
trations were highest at 4 weeks then modestly decreased at subse-
quent visits before stabilizing at week 24. Patients in the tertile with
the greatest BHB increase tended to be male and have higher base-
line FPG levels, lower baseline insulin levels, and longer duration of
T2DM (Table S2). There were no significant differences in back-
ground oral antihyperglycaemic agents across the different tertiles of
ketone response.
In regression analyses relating ΔTKB to changes in other vari-
ables individually (ΔFFA, ΔFPG, ΔTG, ΔLDL-C, ΔHDL-C, ΔBW, ΔSBP
and Δinsulin), the highest correlation was seen with ΔFFA (r2 = 0.16;
P <10−10), with smaller correlations seen with other variables (all
r2 ≤0.03; all P <.01, except ΔSBP, which was not statistically signifi-
cant; Table S3). A joint model that included gender and all statistically
significant terms for change from baseline values in the combined
model (ΔFFA, ΔFPG, ΔTG, ΔHDL-C and ΔBW) gave r2 = 0.22
(Table S3). Thus, while changes in several variables were significantly
correlated with the changes in ketone bodies, only a modest fraction
of the variability observed in the ketone body changes was explained
by the changes in these other variables.
Because ΔFFA was most correlated with ΔTKB, the ratio of
TKB/FFA was calculated to assess whether the mean ΔTKB could be
largely explained by ΔFFA. As shown in Figure S1, the ratio of
TKB/FFA increased, suggesting that the increases in ketone bodies
were more than proportional to increases in FFA.
4 | DISCUSSION
The results of the present study showed that treatment with canagli-
flozin 100 and 200 mg increases serum ketone bodies in Japanese
patients with T2DM. The approximate doubling of median serum
ketone body concentrations is similar to what has been reported in
studies with other SGLT2 inhibitors.13,14 The changes in ketone bod-
ies were considerably greater and more variable than changes in
other metabolic measures, such as glucose, insulin, HbA1c or FFA.
Changes in serum ketones were not fully explained by changes in
plasma fatty acids, suggesting downstream effects of SGLT2 inhibi-
tors on hepatic metabolism that favour ketogenesis.
Intra-subject variability accounted for nearly two-thirds of the
overall variability in ketone responses, which was much higher than
for the other metabolic measures, while inter-subject variability
accounted for one-third of overall variability. Patients in the lowest
tertile of ketone response had no notable mean change in ketones at
any time between week 4 and week 52. Patients in the highest tertile
of ketone response tended to be male and to have longer duration of
T2DM, higher baseline FPG, and lower baseline insulin, which sug-
gests that patients with more advanced T2DM have the highest
ketone body response with canagliflozin.
The pre-treatment variables associated with the greatest increase
in serum ketone body concentrations were higher FPG levels, lower
TABLE 1 Changes from baseline and intraclass correlation coefficient values for different measuresa
Baseline
Median (IQR)
Percent change from baseline
Median (IQR)






BHB, μM 55 (34;97) 78 (2;236) 0.33 135 193
AcAc, μM 28 (19;44) 62 (0;180) 0.34 43 60
TKB, μM 82 (53;141) 73 (1;216) 0.33 177 251
FPG, mmol/L 8.5 (7.4;9.8) −17 (−27;–9) 0.83 1.5 0.66
HbA1c, % 7.9 (7.4;8.6) −11 (−16;–6) 0.91c 0.68 0.22
FFA, μM 510 (380;660) 10 (−15;46) 0.47 149 157
Insulin, pmol/L 47 (30;74) −22 (−40;2) 0.73 26 16
TG, mmol/L 1.4 (1.0;2.0) −15 (−33;9) 0.53 0.76 0.72
LDL cholesterol, mmol/L 3.1 (2.6;3.6) 4 (−6;15) 0.55 0.39 0.36
HDL cholesterol, mmol/L 1.3 (1.1;1.6) 9 (0;19) 0.55 0.14 0.13
UGE, g/g creatinine 0.15 (0.08;0.66) 29400 (7900;51500) 0.68 17000 12000
Abbreviations: AcAc, acetoacetate; BHB, β-hydroxybutyrate; FFA, free fatty acids; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; ICC, intra-
class correlation coefficient; IQR, interquartile range; TG, triglycerides; TKB, total ketone bodies; UGE, urinary glucose excretion.
a Data for both canagliflozin doses were pooled in this analysis.
b The σβ and σϵ values provide measures of inter- and intra-subject variability, respectively, as described in the methods section.
c For HbA1c, only changes after week 12 were included in the analysis to avoid variability associated with the time lag required for equilibration of
HbA1c.
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plasma insulin levels, and greater duration of T2DM. Increases in
ketone bodies were also greater in men than women in this study.
Post-treatment, changes in ketone bodies had the greatest correla-
tions with changes in FFA, while weaker correlations were observed
with other variables, including FPG, BW and insulin. In addition, there
were no significant correlations between the ketone body concentra-
tions in the present study and the ketogenic index proposed by Al
Jobori et al.12 (P = .28); the ketogenic index in the present study was
calculated using the measured values of insulin, glucose and FFA at
each visit rather than after the first treatment day as in Al
Jobori et al.
While most patients in the present study had observed increases
in ketone bodies, nearly all (>99%) of the values were <2 mM. This is
consistent with the infrequent observations of DKA across the cana-
gliflozin clinical programme, which were more likely to occur in
patients who were on insulin or had other precipitating factors (eg,
recent illness, diagnosis of T1DM or latent autoimmune diabetes of
adulthood).10,15 Notably, 1 patient in this study who was treated with
canagliflozin 100 mg added to a sulphonylurea had a severe episode
of DKA shortly after discontinuing study treatment.5 This was the
only case of DKA during the study, and the event was preceded by
infectious gastroenteritis and was suspected to be the result of fulmi-
nant T1DM after viral infection; the patient’s highest TKB level was
13 263 μM.5
In the CANVAS Program, canagliflozin significantly reduced the
risk of major adverse cardiovascular events (MACE; 3-point: cardio-
vascular death, non-fatal myocardial infarction or non-fatal stroke)
compared with placebo in patients with T2DM and a history or high
risk of cardiovascular disease.10 These findings were consistent with
those from the EMPA-REG OUTCOME trial with empagliflozin.9
These data, along with data from recent meta-analyses and real-world
studies, suggest that SGLT2 inhibitors as a class may be associated
with a reduction in cardiovascular risk.9,10,16,17 Consequently, eluci-
dating the potential mechanism of cardioprotection with SGLT2
inhibitors is an active area of research. One possible explanation is
that under conditions of mild hyperketonaemia, such as those caused
by SGLT2 inhibitors, the heart preferentially metabolizes ketone bod-
ies instead of glucose, thereby improving myocardial work efficiency
and function.11 Alternatively, haemodynamic changes associated with
SGLT2 inhibition (ie, BP reduction and reduced intravascular volume)
may decrease the cardiac workload and allow the heart to work more
efficiently.18 Another possibility is that cardioprotection could be
attributable to direct enhancement of myocardial function via
increased levels of glucagon and the natriuretic effect.19
There have been limited data on ketone body changes with cana-
gliflozin to date. In the present study, canagliflozin treatment was
associated with increases in serum ketone bodies that were greater
and more variable than other metabolic measures in Japanese
patients with T2DM. One limitation of the study is that, while day-
to-day changes in diet and exercise probably contribute to the high
within-subject variability in plasma ketone levels, data on within-
subject changes in diet and exercise over the course of the study
were not collected and thus the relationships between changes in
diet and exercise and changes in ketone body concentrations cannot
be determined from this study. Another limitation is that this study
was performed in Japanese patients with a mean body mass index
(BMI) of 26 kg/m2, which is lower than values commonly found in
Western patients with T2DM, and it is possible that individuals with
higher BMI may have different ketone body responses. Future inves-
tigations may help to clarify the sources of variability in serum ketone
bodies and the implications of ketone body elevations in patients
with T2DM treated with SGLT2 inhibitors. In conclusion, increases in
serum ketone bodies with canagliflozin were greater and more vari-
able than changes in other metabolic measures in Japanese patients
with T2DM.
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